Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Johnson & Johnson’s stock rose 1.9% early Wednesday, after the medical tech and drug company posted better-than-expected earnings for the fourth quarter, offsetting mixed guidance. The company had per ...
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.